Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03787992 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Alflutinib Mesylate Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer （FLAG）

StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date changed from estimate of Jun 2021 to Sep 15, 2021
    • Study completion date: Jun 2022 to Mar 2026
    v7
  2. Primary completion date: Jun 2023 to Jun 2021
    • Trial status: Enrolling by Invitation to Active, Not Recruiting
    • Enrollment target: estimated 360 to confirmed 358
    • Study completion date: Aug 31, 2029 to Jun 2022
    v6
  3. Trial status: Not Yet Recruiting to Enrolling by Invitation
    • Start date changed from estimate of Apr 1, 2019 to May 30, 2019
    v5
  4. Study title revisedv4
  5. Study Identification, Study Statusv3
  6. Study title expanded, about 1 wordv2
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
To assess the efficacy and safety of Alflutinib Mesylate versus Gefitinib in patients with locally advanced or Metastatic Non Small Cell Lung Cancer
Trial Details
NCT Number NCT03787992
Lead Sponsor Allist Pharmaceuticals, Inc.
Conditions
(from sponsor)		 Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non-small Cell Lung Cancer
Enrollment 358 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov